About the Authors
- Begoña Comin-Anduix
-
* E-mail: bcomin@mednet.ucla.edu (BCA); aribas@mednet.ucla.edu (AR)
Affiliations Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California, United States of America, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, United States of America
- Hooman Sazegar
-
Affiliation Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
- Thinle Chodon
-
Affiliation Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
- Douglas Matsunaga
-
Affiliation Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
- Jason Jalil
-
Affiliation Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California, United States of America
- Erika von Euw
-
Affiliation Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California, United States of America
- Helena Escuin-Ordinas
-
Affiliation Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
- Robert Balderas
-
Affiliation BD Biosciences, San Jose, California, United States of America
- Bartosz Chmielowski
-
Affiliation Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
- Jesus Gomez-Navarro
-
Current address: Millennium: The Takeda Oncology Company, Cambridge, Massachusetts, United States of America
Affiliation Pfizer Global Research and Development, New London, Connecticut, United States of America
- Richard C. Koya
-
Affiliation Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California, United States of America
- Antoni Ribas
-
* E-mail: bcomin@mednet.ucla.edu (BCA); aribas@mednet.ucla.edu (AR)
Affiliations Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California, United States of America, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, United States of America, Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
Competing Interests
Robert Balderas is an employee of BD Biosciences, the company from which the authors purchased most of the antibodies and reagents for this work. Jesus Gomez-Navarro was an employee of Pfizer Inc, the maker of tremelimumab, at the time that this research was conducted. He now works at Millennium Pharmaceuticals. Antoni Ribas has received research funding and honoraria from Pfizer Inc, the maker of tremelimumab. However, these confilcts did not influence the conduct of the research described in this manuscript, nor the adherence to the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: BCA BC JGN RCK AR. Performed the experiments: BCA HS TC DM JJ EvE HEO RCK. Analyzed the data: BCA HS TC DM JJ RB BC JGN RCK AR. Contributed reagents/materials/analysis tools: BCA TC RB BC JGN RCK AR. Wrote the paper: BCA AR.